News and Events - Catalent
Feb 5, 2024 · Novo Holdings to Acquire Catalent. Feb 5, 2024. Catalent and Novo Holdings have entered into a merger agreement under which Novo Holdings will acquire Catalent in an all-cash transaction that values Catalent at $16.5 billion on an enterprise value basis.
Catalent's Open Letter to Customers Regarding Novo Holdings
Oct 21, 2024 · Catalent Issues Open Letter to Customers Regarding Pending Acquisition by Novo Holdings. Committed to Continuing to Serve Customers and Patients as a Leading Global, Independent, Full-Service CDMO Post-Close. Alessandro Maselli to Remain President and CEO of Catalent Post-Close.
Novo Holdings to Acquire Catalent
Feb 5, 2024 · Novo Holdings will acquire all outstanding shares of Catalent for $63.50 per share in cash. The purchase price represents a premium of 16.5% to the closing price of Catalent’s common stock as of February 2, 2024, the last trading day prior to this announcement, and a 47.5% premium to the 60-day volume-weighted average price as of February 2 ...
Catalent Signs Agreement to Sell Somerset, NJ Oral Solids Facility
Oct 14, 2024 – Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, announced today that it has entered into a definitive agreement to sell its oral solids development and small-scale manufacturing facility in Somerset, NJ to Ardena, a Contract Development and ...
Catalent to Acquire Metrics Contract Services for $475 Million
Aug 9, 2022 · Upon completion, the acquisition will strengthen Catalent’s capabilities in integrated oral solid formulation development, manufacturing, and packaging to help customers simplify and accelerate their programs, while also expanding Catalent’s capacity to …
Moderna and Catalent Partner on COVID-19 Vaccine Candidate
Jun 25, 2020 · Moderna and Catalent today announced a collaboration for large-scale, commercial fill-finish manufacturing of Moderna’s mRNA-based COVID-19 vaccine candidate at Catalent’s biologics facility in Bloomington, Indiana.
Sarepta and Catalent Expand Strategic Manufacturing Partnership
Jan 5, 2023 · Catalent & Sarepta partner to manufacture delandistrogene moxeparvovec, an advanced candidate to treat Duchenne muscular dystrophy.
Catalent Acquires Princeton Cell Therapy Facility from Erytech
Apr 25, 2022 · Catalent's agreement with Erytech Pharma acquires the state-of-the-art cell therapy manufacturing facility in Princeton for $44.5 million.
Catalent Opens Therapy Manufacturing Facilities in Belgium
Dec 8, 2022 · The newly completed facility is the latest addition to Catalent’s Gosselies campus, which already includes a 67,000-square-foot (6,200-square-meter) clinical manufacturing facility offering customers advanced clinical and commercial supply solutions.
Catalent Announces New Operating Structure
Jul 5, 2022 · Catalent's new organizational structure includes a shift from four reporting segments to two, each representing roughly half of the total company revenue.